Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility.
Identifieur interne : 002C12 ( Ncbi/Merge ); précédent : 002C11; suivant : 002C13Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility.
Auteurs : Masayuki Saijo ; Kouichi MoritaSource :
- Uirusu [ 0042-6857 ] ; 2015.
Descripteurs français
- KwdFr :
- MESH :
- pathogénicité : Ebolavirus.
- tendances : Établissements de santé.
- virologie : Fièvre hémorragique à virus Ebola.
- Animaux, Fièvre hémorragique à virus Ebola, Flambées de maladies, Humains, Japon, Protection civile, Sécurité, Virulence.
English descriptors
- KwdEn :
- MESH :
- pathogenicity : Ebolavirus.
- prevention & control : Disease Outbreaks, Hemorrhagic Fever, Ebola.
- trends : Health Facilities.
- virology : Hemorrhagic Fever, Ebola.
- Animals, Civil Defense, Humans, Japan, Safety, Virulence.
Abstract
Although a globe box-type highly contained laboratory with the internationally-recognized biosafety level-4 standards has been constructed in the Murayama Annex, the National Institute of Infectious Diseases, Tokyo, Japan (NIID) in 1981, the laboratory has never been operated as BSL-4 laboratory since its construction. Furthermore, there are no other BSL-4 laboratories in operation in Japan. The evidence indicates that infectious BSL-4 pathogens such as Ebola and Marburg viruses cannot be manipulated in Japan, making it impossible to study the BSL-4 pathogens using the infectious viruses. A large-scale outbreak of ebolavirus disease (EVD) has occurred in the western Africa such as Guinea, Sierra Leone, and Liberia. Furthermore, the highly pathogenic pathogens' infectious diseases outbreaks such as SARS, Nipah encephalitis, Middle East respiratory syndrome (MERS) have emerged in the world. However, BSL-4 laboratories are not present in Japan, making it difficult to study these pathogens and infectious diseases. Because these emerging virus infections are caused by the zoonotic pathogens, the eradiation and the elimination of these infectious diseases are impossible. We need to develop the diagnostics, therapeutics, and preventive measures based on the studies of the highly pathogenic pathogens more in detail using the infectious microbes. Therefore, BSL-4 in operation in Japan is required to minimize the risk of and combat these emerging highly pathogenic pathogens' infectious diseases.
DOI: 10.2222/jsv.65.89
PubMed: 26923962
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C91
- to stream PubMed, to step Curation: 000C91
- to stream PubMed, to step Checkpoint: 000D76
Links to Exploration step
pubmed:26923962Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility.</title>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation><nlm:affiliation>Department of Virology 1, National Institute of Infectious Diseases.</nlm:affiliation>
<wicri:noCountry code="subField">National Institute of Infectious Diseases</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Morita, Kouichi" sort="Morita, Kouichi" uniqKey="Morita K" first="Kouichi" last="Morita">Kouichi Morita</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26923962</idno>
<idno type="pmid">26923962</idno>
<idno type="doi">10.2222/jsv.65.89</idno>
<idno type="wicri:Area/PubMed/Corpus">000C91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C91</idno>
<idno type="wicri:Area/PubMed/Curation">000C91</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C91</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000D76</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000D76</idno>
<idno type="wicri:Area/Ncbi/Merge">002C12</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility.</title>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation><nlm:affiliation>Department of Virology 1, National Institute of Infectious Diseases.</nlm:affiliation>
<wicri:noCountry code="subField">National Institute of Infectious Diseases</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Morita, Kouichi" sort="Morita, Kouichi" uniqKey="Morita K" first="Kouichi" last="Morita">Kouichi Morita</name>
</author>
</analytic>
<series><title level="j">Uirusu</title>
<idno type="ISSN">0042-6857</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Civil Defense</term>
<term>Disease Outbreaks (prevention & control)</term>
<term>Ebolavirus (pathogenicity)</term>
<term>Health Facilities (trends)</term>
<term>Hemorrhagic Fever, Ebola (prevention & control)</term>
<term>Hemorrhagic Fever, Ebola (virology)</term>
<term>Humans</term>
<term>Japan</term>
<term>Safety</term>
<term>Virulence</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Ebolavirus (pathogénicité)</term>
<term>Fièvre hémorragique à virus Ebola ()</term>
<term>Fièvre hémorragique à virus Ebola (virologie)</term>
<term>Flambées de maladies ()</term>
<term>Humains</term>
<term>Japon</term>
<term>Protection civile</term>
<term>Sécurité</term>
<term>Virulence</term>
<term>Établissements de santé (tendances)</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Ebolavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Ebolavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term>
<term>Hemorrhagic Fever, Ebola</term>
</keywords>
<keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Établissements de santé</term>
</keywords>
<keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Health Facilities</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Fièvre hémorragique à virus Ebola</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Hemorrhagic Fever, Ebola</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Civil Defense</term>
<term>Humans</term>
<term>Japan</term>
<term>Safety</term>
<term>Virulence</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Fièvre hémorragique à virus Ebola</term>
<term>Flambées de maladies</term>
<term>Humains</term>
<term>Japon</term>
<term>Protection civile</term>
<term>Sécurité</term>
<term>Virulence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although a globe box-type highly contained laboratory with the internationally-recognized biosafety level-4 standards has been constructed in the Murayama Annex, the National Institute of Infectious Diseases, Tokyo, Japan (NIID) in 1981, the laboratory has never been operated as BSL-4 laboratory since its construction. Furthermore, there are no other BSL-4 laboratories in operation in Japan. The evidence indicates that infectious BSL-4 pathogens such as Ebola and Marburg viruses cannot be manipulated in Japan, making it impossible to study the BSL-4 pathogens using the infectious viruses. A large-scale outbreak of ebolavirus disease (EVD) has occurred in the western Africa such as Guinea, Sierra Leone, and Liberia. Furthermore, the highly pathogenic pathogens' infectious diseases outbreaks such as SARS, Nipah encephalitis, Middle East respiratory syndrome (MERS) have emerged in the world. However, BSL-4 laboratories are not present in Japan, making it difficult to study these pathogens and infectious diseases. Because these emerging virus infections are caused by the zoonotic pathogens, the eradiation and the elimination of these infectious diseases are impossible. We need to develop the diagnostics, therapeutics, and preventive measures based on the studies of the highly pathogenic pathogens more in detail using the infectious microbes. Therefore, BSL-4 in operation in Japan is required to minimize the risk of and combat these emerging highly pathogenic pathogens' infectious diseases.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26923962</PMID>
<DateCompleted><Year>2017</Year>
<Month>03</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0042-6857</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>65</Volume>
<Issue>1</Issue>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>Uirusu</Title>
<ISOAbbreviation>Uirusu</ISOAbbreviation>
</Journal>
<ArticleTitle>Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility.</ArticleTitle>
<Pagination><MedlinePgn>89-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.2222/jsv.65.89</ELocationID>
<Abstract><AbstractText>Although a globe box-type highly contained laboratory with the internationally-recognized biosafety level-4 standards has been constructed in the Murayama Annex, the National Institute of Infectious Diseases, Tokyo, Japan (NIID) in 1981, the laboratory has never been operated as BSL-4 laboratory since its construction. Furthermore, there are no other BSL-4 laboratories in operation in Japan. The evidence indicates that infectious BSL-4 pathogens such as Ebola and Marburg viruses cannot be manipulated in Japan, making it impossible to study the BSL-4 pathogens using the infectious viruses. A large-scale outbreak of ebolavirus disease (EVD) has occurred in the western Africa such as Guinea, Sierra Leone, and Liberia. Furthermore, the highly pathogenic pathogens' infectious diseases outbreaks such as SARS, Nipah encephalitis, Middle East respiratory syndrome (MERS) have emerged in the world. However, BSL-4 laboratories are not present in Japan, making it difficult to study these pathogens and infectious diseases. Because these emerging virus infections are caused by the zoonotic pathogens, the eradiation and the elimination of these infectious diseases are impossible. We need to develop the diagnostics, therapeutics, and preventive measures based on the studies of the highly pathogenic pathogens more in detail using the infectious microbes. Therefore, BSL-4 in operation in Japan is required to minimize the risk of and combat these emerging highly pathogenic pathogens' infectious diseases.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saijo</LastName>
<ForeName>Masayuki</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Virology 1, National Institute of Infectious Diseases.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morita</LastName>
<ForeName>Kouichi</ForeName>
<Initials>K</Initials>
</Author>
</AuthorList>
<Language>jpn</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Japan</Country>
<MedlineTA>Uirusu</MedlineTA>
<NlmUniqueID>0417475</NlmUniqueID>
<ISSNLinking>0042-6857</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002959" MajorTopicYN="Y">Civil Defense</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006268" MajorTopicYN="Y">Health Facilities</DescriptorName>
<QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019142" MajorTopicYN="N">Hemorrhagic Fever, Ebola</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N">Japan</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012449" MajorTopicYN="Y">Safety</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>3</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>3</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26923962</ArticleId>
<ArticleId IdType="doi">10.2222/jsv.65.89</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Morita, Kouichi" sort="Morita, Kouichi" uniqKey="Morita K" first="Kouichi" last="Morita">Kouichi Morita</name>
<name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002C12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:26923962 |texte= Preparedness for ebolavirus disease outbreak in Japan: Necessity of Biosafety level-4 facility. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:26923962" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |